BioPharma Dive January 31, 2023
Dive Brief:
- Drugmakers are allowed to restrict healthcare providers’ use of community and specialty pharmacies to dispense drugs in the 340B drug discount program, a federal appeals court ruled Monday.
- The decision is a win for Sanofi, Novo Nordisk and AstraZeneca. The drugmakers had sued the Department of Health and Human Services after regulators ordered them to stop restricting sales of 340B drugs to contract pharmacies.
- The three-judge panel’s decision reverses a previous ruling in New Jersey against Novo Nordisk and Sanofi, and upholds one from Delaware in favor of AstraZeneca. It’s the first decision from three federal appeals courts that are considering lawsuits over the pharmaceutical companies’ 340B restrictions.
Dive Insight:
Healthcare providers and drugmakers have been...
Today's Sponsors
Today's Sponsor